Dioscin alleviates cardiomyocyte pyroptosis in acute myocardial infarction rats via regulating LncRNA FGD5-AS1/miR-424/HOXA3 axis

Acute myocardial infarction (AMI) is a severe cardiovascular condition. Recently, it has been discovered that dioscin plays pivotal roles in the domains of anti-inflammatory, antiviral, and anti-tumor activities. However, Nevertheless, the precise impact and mechanism by which dioscin protects against cardiomyocyte pyroptosis in AMI remains unclear. This study aimed to determine the significance and investigate the mechanisms by which dioscin affects cardiomyocyte pyroptosis in cases of acute myocardial infarction. In this study, rats were divided into four distinct groups: sham, AMI, AMI + Negative Control (NC), and AMI + FGD5 Antisense RNA 1 (FGD5-AS1). Subsequently, quantitative real-time polymerase chain reaction (qPCR) assay, quantification of infarct size, and enzyme linked immunosorbent assay (ELISA) assay were used to confirm the expression of FGD5-AS1 after AMI surgeries. The results indicated that, expression of FGD5-AS1 was significantly decreased. Furthermore, it was determined that FGD5-AS1 can alleviate myocardial damage induced by AMI. Methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay and western blot assay results indicated that FGD5-AS1 promoted cell proliferation and decreased the inflammatory response and pyroptosis of cardiomyocytes induced by hypoxia/re-oxygenation (H/R). In addition, a combination of bioinformatics approaches, dual-luciferase reporter assay, and RNA pull down assay were used to predict and confirm the interaction between FGD5-AS1, microRNA-424 (miR-424), and Homeobox A3 (HOXA3). It was observed that FGD5-AS1 facilitates cell proliferation and alleviate H/R-induced inflammatory response and cardiomyocyte pyroptosis by regulating HOXA3 expression. Finally, the confirmation of dioscin’s ability to mitigate myocardial damage and cardiomyocyte pyroptosis resulting from acute myocardial infarction (AMI) and regulating the expression of FGD5-AS1/miR-424/HOXA3 axis was established. Together, this research demonstrates that dioscin effectively reduces cardiomyocyte pyroptosis in rats with acute myocardial infarction (AMI) by modulating long non-coding RNA (LncRNA) FGD5-AS1/miR-424/HOXA3 axis.

Acute myocardial infarction; Cardiomyocyte pyroptosis; Dioscin; LncRNA FGD5-AS1; miR-424; HOXA3

[1] Lindahl B, Mills NL. A new clinical classification of acute myocardial infarction. Nature Medicine. 2023; 29: 2200–2205.

[2] Krittanawong C, Khawaja M, Tamis‐Holland JE, Girotra S, Rao SV. Acute myocardial infarction: etiologies and mimickers in young patients. Journal of the American Heart Association. 2023; 12: e029971.

[3] Chai R, Ye Z, Xue W, Shi S, Wei Y, Hu Y, et al. Tanshinone IIA inhibits cardiomyocyte pyroptosis through TLR4/NF-κB p65 pathway after acute myocardial infarction. Frontiers in Cell and Developmental Biology. 2023; 11: 1252942.

[4] Li Z, Xu H, Liu X, Hong Y, Lou H, Liu H, et al. GDF11 inhibits cardiomyocyte pyroptosis and exerts cardioprotection in acute myocardial infarction mice by upregulation of transcription factor HOXA3. Cell Death & Disease. 2020; 11: 917.

[5] Yarovinsky TO, Su M, Chen C, Xiang Y, Tang WH, Hwa J. Pyroptosis in cardiovascular diseases: pumping gasdermin on the fire. Seminars in Immunology. 2023; 69: 101809.

[6] Sun Y, Chu S, Wang R, Xia R, Sun M, Gao Z, et al. Non-coding RNAs modulate pyroptosis in myocardial ischemia-reperfusion injury: a comprehensive review. International Journal of Biological Macromolecules. 2024; 257: 128558.

[7] Li X, Liu S, Qu L, Chen Y, Yuan C, Qin A, et al. Dioscin and diosgenin: insights into their potential protective effects in cardiac diseases. Journal of Ethnopharmacology. 2021; 274: 114018.

[8] Tao X, Xu L, Yin L, Han X, Qi Y, Xu Y, et al. Retraction Note: dioscin induces prostate cancer cell apoptosis through activation of estrogen receptor-β. Cell Death & Disease. 2021; 12: 800.

[9] Wang P, Wang C, Liu C. Antitumor effects of dioscin in A431 cells via adjusting ATM/p53-mediated cell apoptosis, DNA damage and migration. Oncology Letters. 2021; 21: 59.

[10] Xi P, Niu Y, Zhang Y, Li W, Gao F, Gu W, et al. The mechanism of dioscin preventing lung cancer based on network pharmacology and experimental validation. Journal of Ethnopharmacology. 2022; 292: 115138.

[11] Busscher D, Boon R, Juni R. The multifaceted actions of the lncRNA H19 in cardiovascular biology and diseases. Clinical Science. 2022; 136: 1157–1178.

[12] Haybar H, Sadati NS, Purrahman D, Mahmoudian-Sani MR, Saki N. LncRNA TUG1 as potential novel biomarker for prognosis of cardiovascular diseases. Epigenomics. 2023; 15: 1273–1290.

[13] Wo Y, Guo J, Li P, Yang H, Wo J. Long non-coding RNA CHRF facilitates cardiac hypertrophy through regulating Akt3 via miR-93. Cardiovascular Pathology. 2018; 35: 29–36.

[14] Yang J, Huang X, Hu F, Fu X, Jiang Z, Chen K. LncRNA ANRIL knockdown relieves myocardial cell apoptosis in acute myocardial infarction by regulating IL-33/ST2. Cell Cycle. 2019; 18: 3393–3403.

[15] Sun F, Zhuang Y, Zhu H, Wu H, Li D, Zhan L, et al. LncRNA PCFL promotes cardiac fibrosis via miR-378/GRB2 pathway following myocardial infarction. Journal of Molecular and Cellular Cardiology. 2019; 133: 188–198.

[16] Shen LS, Hu XF, Chen T, Shen GL, Cheng D. Integrated network analysis to explore the key mRNAs and lncRNAs in acute myocardial infarction. Mathematical Biosciences and Engineering. 2019; 16: 6426–6437.

[17] Zhang XQ, Song LH, Feng SJ, Dai XM. LncRNA FGD5-AS1 acts as a competing endogenous RNA for miRNA-223 to lessen oxygen-glucose deprivation and simulated reperfusion (OGD/R)-induced neurons injury. Folia Neuropathologica. 2019; 57: 357–365.

[18] Chen H, Lan Z, Li Q, Li Y. Abnormal expression of long noncoding RNA FGD5-as1 affects the development of periodontitis through regulating miR-142-3p/SOCS6/NF-κB pathway. Artificial Cells, Nanomedicine, and Biotechnology. 2019; 47: 2098–2106.

[19] National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the care and use of laboratory animals. 8th edn. National Academies Press: Washington (DC). 2011.

[20] Sun HY, Wang XL, Ma LC, Yang M, Yang HJ, Huang HW, et al. Influence of MiR-154 on myocardial apoptosis in rats with acute myocardial infarction through Wnt/β-catenin signaling pathway. European Review for Medical and Pharmacological Sciences. 2019; 23: 818–825.

[21] Bandopadhyay S, Anand U, Gadekar VS, Jha NK, Gupta PK, Behl T, et al. Dioscin: a review on pharmacological properties and therapeutic values. BioFactors. 2022; 48: 22–55.

[22] Zhao S, Heng N, Weldegebriall Sahlu B, Wang H, Zhu H. Long Noncoding RNAs: recent insights into their role in male infertility and their potential as biomarkers and therapeutic targets. International Journal of Molecular Sciences. 2021; 22: 13579.

[23] Zhu X, Du L, Zhang L, Ding L, Xu W, Lin X. The critical role of toll-like receptor 4 in bone remodeling of osteoporosis: from inflammation recognition to immunity. Frontiers in Immunology. 2024; 15: 1333086.

[24] Yang L, Zhang Y, Wang L, Fan F, Zhu L, Li Z, et al. Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22. Journal of Hepatology. 2010; 53: 339–347.

[25] Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. The Lancet. 2011; 378: 182–197.

[26] Yang Y, Dong MH, Hu HM, Min QH, Xiao L. LncRNA FGD5-AS1 /miR-5590-3p axis facilitates the proliferation and metastasis of renal cell carcinoma through ERK/AKT signalling. European Review for Medical and Pharmacological Sciences. 2020; 24: 8756–8766.

[27] Wu L, Zhu X, Song Z, Guo M, Liang J, Yan D. FGD5-AS1 facilitates glioblastoma progression by activation of Wnt/β-catenin signaling via regulating miR-129-5p/HNRNPK axis. Life Sciences. 2020; 256: 117998.

[28] He N, Xiang L, Chen L, Tong H, Wang K, Zhao J, et al. The role of long non-coding RNA FGD5-AS1 in cancer. Bioengineered. 2022; 13: 11026–11041.

[29] Qin S, Liu Y, Zhang X, Huang P, Xia L, Leng W, et al. LncRNA FGD5-AS1 is required for gastric cancer proliferation by inhibiting cell senescence and ROS production via stabilizing YBX1. Journal of Experimental & Clinical Cancer Research. 2024; 43: 188.

[30] Zhu F, Niu R, Shao X, Shao X. FGD5‑AS1 promotes cisplatin resistance of human lung adenocarcinoma cell via the miR‑142‑5p/PD‑L1 axis. International Journal of Molecular Medicine. 2021; 47: 523–532.

[31] Su D, Ji Z, Xue P, Guo S, Jia Q, Sun H. Long-Noncoding RNA FGD5-AS1 enhances the viability, migration, and invasion of glioblastoma cells by regulating the miR-103a-3p/TPD52 axis. Cancer Management and Research. 2020; 12: 6317–6329.

[32] Zhong H, Hao L, Li X, Wang C, Wu X. Anti-inflammatory role of trilobatin on lipopolysaccharide-induced acute lung injury through activation of AMPK/GSK3β-Nrf2 pathway. Signa Vitae. 2020; 16: 160–166.

[33] Lou Y, Wang S, Qu J, Zheng J, Jiang W, Lin Z, et al. miR-424 promotes cardiac ischemia/reperfusion injury by direct targeting of CRISPLD2 and regulating cardiomyocyte pyroptosis. International Journal of Clinical and Experimental Pathology. 2018; 11: 3222–3235.

[34] Zhao Y, Zhu C, Chang Q, Peng P, Yang J, Liu C, et al. MiR-424-5p regulates cell cycle and inhibits proliferation of hepatocellular carcinoma cells by targeting E2F7. PLOS ONE. 2020; 15: e0242179.